Avantogen’s CEO joins Hawaii Biotech Board of Directors

23-Oct-2008 - Australia

Avantogen Ltd announced the appointment of Dr William Ardrey, CEO of Avantogen, to the Board of Directors of Hawaii Biotech Inc effective 21 October 2008. Avantogen is focused on commercial licensing and revenue outcomes throughout the group. Avantogen believes that Dr. Ardrey’s appointment to the Hawaii Biotech Board will advance these goals.

Avantogen is a significant investor in Hawaii Biotech and intends to purchase additional shares in the company based on proceeds received from Avantogen’s recent $1 million capital raising.

"The Board of Avantogen is firmly convinced that Hawaii Biotech's recombinant DNA manufacturing platform is an excellent investment opportunity, and Avantogen actively seeks to increase its stake in this promising vaccine development company," stated Avantogen Chairman Patrick Elliott.

Hawaii Biotech Inc recently announced initiation of a Phase I West Nile Virus vaccine clinical trial, development of partnerships with PDVI/Bill & Melinda Gates Foundation and the Walter Reed Army Institute of Research, and recruitment of Professor Ian Frazer to the Scientific Advisory Board of Hawaii Biotech Inc. Hawaii Biotech anticipates participating in a Walter Reed sponsored Phase I human clinical trial with their Dengue vaccine candidate early next calendar year.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances